wIRA superficial hyperthermia

 

At Dr. Markus Notter (Lindenhofspital Bern - Radioonkologie) presented at the ESHO Annual Meeting, the 22.-25th of May 2019 in Warszawa, an evaluation of 113 patients with preirradiated macroscopic locally recurrent breast cancer (mostly large-sized and inflammatory), who have been treated with wIRA superficial hyperthermia directly following hypofractionated radiotherapy with 5 x 4 Gy, 1x/week (= 20 Gy total reirradiation dose).

Response and local control rates were differentiated by 4 defined tumor sizes.

Corresponding to the characteristics of this disease (high portion of Lymphangiosis carcinomatosa), 51 patients suffered from a new re-recurrence after complete remission (CR) or from a new progression after partial remission (PR).

In 40 of these patients the same protocol was applied another time (hyperthermia + re-re-irradiation),  in order to achieve tumor control resp. stabilization.
No acute or chronic (radiotherapy- or hyperthermia-related) adverse effects > grade 2 were observed. Grade 2 adverse effects were limited to teleangiectasia.
By combining wIRA superficial hyperthermia and hypofractionated repeat reirradiation, repeatedly recurrent Lymphangiosis Carcinomatosa can be treated well and sometimes even stabilized for years.

Look at ABSTRACT

 

 

 

Print Email


heckel medizintechnik GmbH

Olgastrasse 25
73728 Esslingen

Tel: ++49 (0)711 - 128989 - 0
Fax: ++49 (0)711 - 128989 - 20

info@heckel-medizintechnik.de

PARTNER OF

 

hydrosun

PARTNER OF
 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.